The Toronto-based firm listed on the Canadian Securities Exchange under the ticker symbol MEND at $0.90 a share Wednesday. Its debut follows an oversubscribed initial public offering, through which it raised about $9.2 million, up from its target of between $5 million to $8 million. Canaccord Genuity and Beacon Securities acted as agents in the IPO. (The Logic)

Talking point: The company’s stock price closed at $1.65. The IPO follows listings by other health-related startups, including Dialogue Health Technologies and MindBeacon. Another telehealth firm, Maple, is also preparing for an IPO. The lesser-known Nurosene was founded last year by Halifax-based Daniel Gallucci, a functional neurologist and researcher who previously ran a clinical practice helping athletes and other patients recover from brain injuries. In December 2020, the company brought on former Beats Music corporate-strategy vice-president Ranj Bath as CEO. The firm—which also unveiled NFL player Richard Sherman as an investor and ambassador—only recently launched its app, which focuses on improving mental health and brain health. But Bath told The Logic that going public early rather than raising venture capital will help fund the young business without having to bend to VCs’ ideals. He said it could also make it easier for the firm to pursue acquisitions, which Bath said is a core part of its growth strategy.